DEBORAH WATERHOUSE
CEO, ViiV Healthcare and President, Global Health, GSK
Deborah Waterhouse was appointed to the GSK Leadership Team on 8 January 2020. She became Chief Executive Officer of ViiV Healthcare on 1 April 2017. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders. In addition to leadership of the HIV business, she also leads GSK's Global Health organisation.
Deborah joined GSK in 1996 and was most recently the Senior Vice President of Primary Care within the company’s US business, prior to which she led the US Vaccines business.
She brings a wealth of experience to GSK having lived and worked in Europe, Asia Pacific and the USA, and a strong track record of performance in both speciality and primary care.
Deborah led the HIV business in the UK before heading the HIV Centre of Excellence for Pharma Europe, and held international roles as General Manager of Australia and New Zealand and Senior Vice President for Central and Eastern Europe.
READ ARTICLES WRITTEN BY DEBORAH
40 years of progress but stigma still prevails
Despite the progress made in the treatment of HIV, many still come face to face with stigma and it is imperative that we come together to challenge these outdated views.
Our Executive Team
YOU MAY ALSO BE INTERESTED IN
Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.
Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.
NP-GBL-HVX-COCO-220025 December 2024
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
